The Addition of Dexmedetomidine on Postoperative Sleep for Middle-aged and Elderly Patients With Gastric Cancer

The Addition of Dexmedetomidine on Postoperative Sleep for Middle-aged and Elderly Patients With Gastric Cancer: A Prospective Randomized Clinical Trial

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03117023

Enrollment

Registered

2017-04-17

Start date

2017-04-15

Completion date

2017-06-01

Last updated

2017-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

dexmedetomidine, sleep deprivation, gastric cancer, middle-aged and elderly patient

Brief summary

The purpose of this study is to find out the effect of Dexmedetomidine for treatment of sleep deprivation, pain relief and postoperative recovery on middle-aged and elderly Patients with Gastric Cancer.

Detailed description

Patients were randomized to receive sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h (DEX group) or sufentanil 0.05ug/kg/h + saline (control group) for 48h. The primary outcome was the total sleep time during the first three days after surgery. The secondary outcomes included pain score, daily sufentanil consumption, time to functional recovery, length of hospital stay and side effects.

Interventions

DRUGdexmedetomidine

sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

Elective gastric cancer operation Age ≧ 55 years ASA classification：I to III, BMI: 18-30 kg/m2 without the history of gastrointestinal surgery the normal coagulation function -

Exclusion criteria

the history of gastrointestinal surgery Gastrostomy and jejunostomy sleep apnea syndrome or severe osahs Severe liver and heart dysfunction Severe mental illness \-

Design outcomes

Primary

Measure	Time frame	Description
sleep time	during the first three days after surgery	total sleep time during the first three days after surgery

Secondary

Measure	Time frame	Description
pain score	during the first three days after surgery	pain score measure
daily sufentanil consumption	during the first three days after surgery	daily sufentanil consumption
functional recovery	during the first three days after surgery	time to functional recovery
length of hospital stay	during the first three days after surgery	length of hospital stay
side effects	during the first three days after surgery	lethargy and mental sluggishness

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026